Drug reference

edrophonium

Noncovalent cholinesterase inhibitor · Diagnostic Agent; Antiarrhythmic (supraventricular tachycardia)

Noncovalent cholinesterase inhibitorDiagnostic Agent; Antiarrhythmic (supraventricular tachycardia)

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactions

SiponimodSevereDatabaseDDInter

Mechanism

Edrophonium, a quaternary cation, reversibly binds to the choline subsite in the active center of acetylcholinesterase (AChE). This noncovalent association sterically blocks acetylcholine from entering the active site for catalysis.

Indications

antagonize the action of nondepolarizing muscle relaxantsdiagnosis of myasthenia gravis

Pharmacokinetics

Duration

Brief duration of action

Excretion

Rapid renal elimination

Drug interactions

Siponimod

Severe

Database

Clinical effect not specified

Source: DDInter

11 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.

Related guidelines

Leprosy

ICMR · Dermatology · 2021

Heart failure in diabetes

RSSDI · Cardiology · 2023

Hypertension in adults

ICMR · Cardiology · 2019

Gestational diabetes mellitus

FOGSI · Obstetrics & Gynaecology · 2023

Fetal growth restriction

FOGSI · Obstetrics & Gynaecology · 2018

Other Noncovalent cholinesterase inhibitor drugs

tacrine

0 brands

Ask House about edrophonium

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e·Updated: 2026-05-10